Immuron Limited requests trading halt

Immuron Limited (ASX: $IMC) has requested an immediate trading halt for its securities in order to analyze data before making an announcement of Phase 2 IMM-124E clinical trial top-line results. The trading halt is expected to remain in place until the announcement is made or until the market opens on 7 March 2024, whichever is earlier.

Company's request for trading halt explained

The trading halt request by Immuron Limited is aimed at ensuring that the company has sufficient time to thoroughly analyze and interpret the data related to the Phase 2 IMM-124E clinical trial top-line results before making the announcement. This step reflects the company's commitment to providing accurate and well-considered information to the market.

Summary of Immuron's trading halt request

Immuron Limited (ASX: $IMC) has requested a trading halt to analyze data before announcing the Phase 2 IMM-124E clinical trial top-line results. The company aims to ensure that the market receives well-informed and carefully considered information. This move demonstrates Immuron's dedication to transparency and accuracy in its communications with the market.